AU2015317509A1 - Injectable formulations for treating cancer - Google Patents

Injectable formulations for treating cancer Download PDF

Info

Publication number
AU2015317509A1
AU2015317509A1 AU2015317509A AU2015317509A AU2015317509A1 AU 2015317509 A1 AU2015317509 A1 AU 2015317509A1 AU 2015317509 A AU2015317509 A AU 2015317509A AU 2015317509 A AU2015317509 A AU 2015317509A AU 2015317509 A1 AU2015317509 A1 AU 2015317509A1
Authority
AU
Australia
Prior art keywords
formulation
cancer
compound
cell
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015317509A
Other languages
English (en)
Inventor
Angelos Dovletoglou
Edward James Olhava
Bruce Rehlaender
Steve Wald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of AU2015317509A1 publication Critical patent/AU2015317509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015317509A 2014-09-17 2015-09-17 Injectable formulations for treating cancer Abandoned AU2015317509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051904P 2014-09-17 2014-09-17
US62/051,904 2014-09-17
PCT/US2015/050785 WO2016044649A1 (en) 2014-09-17 2015-09-17 Injectable formulations for treating cancer

Publications (1)

Publication Number Publication Date
AU2015317509A1 true AU2015317509A1 (en) 2017-03-16

Family

ID=55533871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015317509A Abandoned AU2015317509A1 (en) 2014-09-17 2015-09-17 Injectable formulations for treating cancer

Country Status (6)

Country Link
US (3) US20170290765A1 (cg-RX-API-DMAC7.html)
EP (1) EP3193879A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017527567A (cg-RX-API-DMAC7.html)
AU (1) AU2015317509A1 (cg-RX-API-DMAC7.html)
CA (1) CA2960287A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016044649A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
WO2014152566A2 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
JP2006199588A (ja) * 2003-05-06 2006-08-03 Senju Pharmaceut Co Ltd オキサゾリジノン誘導体含有水性液剤
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20080219927A1 (en) * 2007-01-18 2008-09-11 Thakur Ajit B Adenosine derivative formulations for medical imaging
CN101686681B (zh) * 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
CN103391939B (zh) * 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
WO2014026198A1 (en) * 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (en) * 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
JP2016510316A (ja) * 2012-12-21 2016-04-07 エピザイム,インコーポレイティド 白血病の治療に使用するためのdot1l阻害剤
US20160022725A1 (en) * 2013-03-15 2016-01-28 Epizyme, Inc. Injectable formulations for treating cancer

Also Published As

Publication number Publication date
EP3193879A4 (en) 2018-05-16
CA2960287A1 (en) 2016-03-24
US20210251887A1 (en) 2021-08-19
US20190388335A1 (en) 2019-12-26
EP3193879A1 (en) 2017-07-26
WO2016044649A1 (en) 2016-03-24
JP2017527567A (ja) 2017-09-21
US20170290765A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US20200113923A1 (en) Dot1l inhibitors for use in the treatment of leukemia
US20220160721A1 (en) Methods of treating cancer
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
AU2013361076A1 (en) DOT1 L inhibitors for use in the treatment of leukemia
US11572383B2 (en) Methods of synthesizing substituted purine compounds
EP2892536B1 (en) Method of treating leukemia
US20210353661A1 (en) Injectable formulations for treating cancer
US10143704B2 (en) Methods for treating cancer
EP3630080A1 (en) Use of ezh2 inhibitors for treating cancer
US20210251887A1 (en) Injectable formulations for treating cancer
US20180028552A1 (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period